ScholarIQanswers from OpenAlex & ORCID
Lars Lindholm
ResearcherPublications, citations & collaboration network
Lars Lindholm is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Lars Lindholm have?
ScholarIQindexed works
Lars Lindholm has 499 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Lars Lindholm have?
ScholarIQcitation count
Lars Lindholm has 35,589 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Lars Lindholm?
ScholarIQh-index
Lars Lindholm has an h-index of 66 in OpenAlex.
What is the i10-index of Lars Lindholm?
ScholarIQi10-index
Lars Lindholm has an i10-index of 258 in OpenAlex.
What is the ORCID of Lars Lindholm?
ScholarIQorcid
The ORCID for Lars Lindholm is on the source record.
What is the OpenAlex record for Lars Lindholm?
ScholarIQopenalex
The OpenAlex for Lars Lindholm is on the source record.
What are the most-cited papers on Lars Lindholm?
ScholarIQmost cited works
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Björn Dahlöf, Richard B. Devereux, Sverre E. Kjeldsen, Stevo Julius, Gareth Beevers, Ulf dé Fairé, Frej Fyhrquist, Hans Ibsen, Krister Kristiansson, Ole Lederballe‐Pedersen, Lars Lindholm, Markku S. Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members:, G. Mancia, Guy De Backer, Anna F. Dominiczak, Renata Cífková, R. Fagard, Giuseppe Germanò, Guıdo Grassı, A. M. Heagerty, SE Kjeldsen, S. Laurent, Krzysztof Narkiewicz, Luís M. Ruilope, Andrzej Rynkiewicz, Roland E. Schmieder, Harry A.J. Struijker Boudier, Alberto Zanchetti, Alec Vahanian, A. John Camm, Raffaele De Caterina, V. Dean, Kenneth Dickstein, G. Filippatos, Christian Funck‐Brentano, Irene Hellemans, S. D. Kristensen, Keith McGregor, U Sechtem, Sigmund Silber, Michał Tendera, P. Widimsky, José Luis Zamorano, SE Kjeldsen, Serap Erdine, Krzysztof Narkiewicz, W. Kiowski, Enrico Agabiti‐Rosei, E Ambrosioni, Renata Cífková, Anna F. Dominiczak, R. Fagard, A. M. Heagerty, S. Laurent, Lars Lindholm, G. Mancia, Athanasios Manolis, Peter M. Nilsson, Josep Redón, Roland E. Schmieder, Harry A.J. Struijker-Boudier, Margus Viigimaa, Document Reviewers:, G. Filippatos, Stamatis Adamopoulos, Enrico Agabiti‐Rosei, E Ambrosioni, Vicente Bertoméu, D Clément, Serap Erdine, Csaba Farsang, D. Gaita, W. Kiowski, Gregory Y.H. Lip, Jean-Michel Mallion, Athanasios Manolis, Peter M. Nilsson, Eoin O’Brien, Piotr Ponikowski, Josep Redón, Frank Ruschitzka, Juan Tamargo, PA van Zwieten, Margus Viigimaa, Bernard Waeber, Bryan Williams, José Luis Zamorano
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Lennart Hansson, Lars Lindholm, Leo Niskanen, Jan Lanke, Thomas Hedner, Anders Niklason, K Luomanmäki, Björn Dahlöf, Ulf dé Fairé, Claes Mörlin, Bengt E. Karlberg, P-O Wester, Jan-Erik Björck
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Björn Dahlöf, L. Hansson, Lars Lindholm, Bengt Scherstén, Tord Ekbom, P-O Wester
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lars Lindholm, Hans Ibsen, Björn Dahlöf, Richard B. Devereux, Gareth Beevers, Ulf dé Fairé, Frej Fyhrquist, Stevo Julius, Sverre E. Kjeldsen, Krister Kristiansson, Ole Lederballe‐Pedersen, Markku S. Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Peter Aurup, Jonathan M. Edelman, Steven Snapinn